In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass

Nuclear Medicine and Biology

Volumn 37, Issue 3, 2010, Pages 265-275

  Velikyan, Irina ^a,b   Sundin, Anders ^c   Eriksson, Barbro ^d   Lundqvist, Hans ^e   Sörensen, Jens ^d   Bergström, Mats ^a   Långström, Bengt ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BIACORE AB   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

68Ga; 68Ga DOTATOC; Dosimetry; Neuroendocrine; Octreotide; PET; Somatostatin; Specific radioactivity

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PHENYLTYROSINE OCTREOTIDE GA 68; 4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; ALPHA INTERFERON; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; OCTREOTIDE; SOMATOSTATIN RECEPTOR; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GA(III) DOTATOC; GA(III)-DOTATOC; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; FEMALE; HUMAN; IN VIVO STUDY; KIDNEY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MICROWAVE COOKING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; QUALITY CONTROL; RADIOACTIVITY; SPLEEN; TUMOR VOLUME; METABOLISM; MIDDLE AGED; PILOT STUDY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN;

EID: 77950297123     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.11.008     Document Type: Article

References (31)

1. Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97:934-959.
2. Quaedvlieg P.F., Visser O., Lamers C.B., Janssen-Heijen M.L., Taal B.G. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001, 12:1295-1300.
3. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
4. Oberg K., Kvols L., Caplin M., Delle Fave G., de Herder W., Rindi G., et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15:966-973.
5. Reubi J.C., Schär J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging 2000, 27:273-282.
6. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005, 32:724.
7. Pettinato C., Sarnelli A., Di Donna M., Civollani S., Nanni C., Montini G., et al. (68)Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008, 35:72-79.
8. Waser B., Tamma M.L., Cescato R., Maecke H.R., Reubi J.C. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009, 50:936-941.
9. de Herder W.W., Kwekkeboom D.J., Valkema R., Feelders R.A., van Aken M.O., Lamberts S.W., et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 2005, 28:132-136.
10. Modlin I.M., Kidd M., Latich I., Zikusoka M.N., Shapiro M.D. Current status of gastrointestinal carcinoids. Gastroenterology 2005, 128:1717-1751.
11. Waldherr C., Pless M., Maecke H.R., Schumacher T., Crazzolara A., Nitzsche E.U., et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002, 43:610-616.
12. Forrer F., Valkema R., Kwekkeboom D.J., de Jong M., Krenning E.P. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007, 21:111-129.
13. Pauwels P., Debiec-Rychter M., Stul M., De Wever I., Van Oosterom A.T., Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 2005, 47:41-47.
14. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003, 30:510-518.
15. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004, 31:1386-1392.
16. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 2007, 28:359-363.
17. 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging 2006, 33:506.
18. 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005, 46:763-769.
19. 68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 2006, 65:222-227.
20. Wei L., Miao Y., Gallazzi F., Quinn T.P., Welch M.J., Vavere A.L., et al. Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol 2007, 34:945-953.
21. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48:508-518.
22. Hofmann M., Weitzel T., Krause T. Ga-68-DOTATOC: Feasibility of high throughput screening by small animal PET using a clinical high-resolution PET/CT scanner. Nucl Instrum Methods Physics Res Sec A: Accelerators, Spectrometers, Detectors Assoc Equipment 2006, 569:522-524.
23. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003, 5:42-48.
24. 68Ga-bioconjugates with high specific radioactivity. Bioconjug Chem 2004, 15:554-560.
25. Velikyan I., Långström B. Microwave method for preparing radiolabelled gallium complexes. WO 2004/089425, 2004.
26. Velikyan I., Långström B., and Beyer G. Method of obtaining gallium-68 and use thereof and device for carrying out said method. WO 2004/089517, 2004.
27. 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration. Nucl Med Biol 2003, 30:253-260.
28. de Jong M., Breeman W.A., Bernard B.F., van Gameren A., de Bruin E., Bakker W.H., et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999, 26:693-698.
29. Velikyan I., Beyer G.J., Bergstrom-Pettermann E., Johansen P., Bergstrom M., Langstrom B. The importance of high specific radioactivity in the performance of (68)Ga-labeled peptide. Nucl Med Biol 2008, 35:529-536.
30. 18F-FDG. Cancer 2008, 112:2447-2455.
31. Wahl R.L. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005, 46(Suppl 1):128S-140S.